COSMOS Pharmaceutical Past Earnings Performance
Past criteria checks 3/6
COSMOS Pharmaceutical has been growing earnings at an average annual rate of 2.6%, while the Consumer Retailing industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 8.3% per year. COSMOS Pharmaceutical's return on equity is 11%, and it has net margins of 2.6%.
Key information
2.6%
Earnings growth rate
2.6%
EPS growth rate
Consumer Retailing Industry Growth | 7.8% |
Revenue growth rate | 8.3% |
Return on equity | 11.0% |
Net Margin | 2.6% |
Next Earnings Update | 10 Jan 2025 |
Recent past performance updates
Recent updates
COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business
Nov 18We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Sep 26An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued
Aug 17COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends
Aug 01Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price
Jun 28We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Jun 10COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 17Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio
Mar 16Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture
Feb 28Revenue & Expenses Breakdown
How COSMOS Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Aug 24 | 985,177 | 26,089 | 162,218 | 0 |
31 May 24 | 964,989 | 24,454 | 138,536 | 0 |
29 Feb 24 | 936,706 | 24,871 | 136,590 | 0 |
30 Nov 23 | 900,111 | 24,085 | 132,074 | 0 |
31 Aug 23 | 863,228 | 23,824 | 127,436 | 0 |
31 May 23 | 827,697 | 23,797 | 122,807 | 0 |
28 Feb 23 | 802,831 | 22,983 | 120,343 | 0 |
30 Nov 22 | 788,292 | 23,209 | 116,369 | 0 |
31 Aug 22 | 772,127 | 23,393 | 111,717 | 0 |
31 May 22 | 755,414 | 23,155 | 107,756 | 0 |
28 Feb 22 | 743,612 | 22,030 | 105,901 | 0 |
30 Nov 21 | 733,387 | 25,329 | 103,047 | 0 |
31 Aug 21 | 726,672 | 25,909 | 101,013 | 0 |
31 May 21 | 726,424 | 27,156 | 99,163 | 0 |
28 Feb 21 | 733,223 | 28,777 | 97,373 | 0 |
30 Nov 20 | 723,309 | 25,736 | 96,058 | 0 |
31 Aug 20 | 709,064 | 23,876 | 94,907 | 0 |
31 May 20 | 684,403 | 21,435 | 93,347 | 0 |
29 Feb 20 | 653,527 | 20,217 | 92,041 | 0 |
30 Nov 19 | 638,034 | 18,951 | 90,020 | 0 |
31 Aug 19 | 622,103 | 19,349 | 87,408 | 0 |
31 May 19 | 611,137 | 19,185 | 85,050 | 0 |
28 Feb 19 | 597,715 | 18,966 | 83,467 | 0 |
30 Nov 18 | 585,536 | 18,857 | 81,088 | 0 |
31 Aug 18 | 572,807 | 17,880 | 78,901 | 0 |
31 May 18 | 557,999 | 17,633 | 76,680 | 0 |
28 Feb 18 | 542,936 | 17,510 | 76,050 | 0 |
30 Nov 17 | 526,523 | 17,313 | 73,538 | 0 |
31 Aug 17 | 514,880 | 18,239 | 70,898 | 0 |
31 May 17 | 502,732 | 18,215 | 68,097 | 0 |
28 Feb 17 | 490,037 | 15,812 | 66,302 | 0 |
30 Nov 16 | 477,739 | 14,981 | 64,010 | 0 |
31 Aug 16 | 463,517 | 13,679 | 61,636 | 0 |
31 May 16 | 447,273 | 12,435 | 59,442 | 0 |
29 Feb 16 | 433,328 | 12,738 | 59,223 | 0 |
30 Nov 15 | 423,817 | 12,474 | 57,702 | 0 |
31 Aug 15 | 414,046 | 12,350 | 55,833 | 0 |
31 May 15 | 408,466 | 11,694 | 54,095 | 0 |
28 Feb 15 | 402,690 | 10,671 | 54,091 | 0 |
30 Nov 14 | 392,527 | 10,286 | 51,806 | 0 |
31 Aug 14 | 382,823 | 10,193 | 50,230 | 0 |
31 May 14 | 371,825 | 10,600 | 48,517 | 0 |
28 Feb 14 | 360,162 | 10,366 | 47,996 | 0 |
Quality Earnings: 3349 has high quality earnings.
Growing Profit Margin: 3349's current net profit margins (2.6%) are lower than last year (2.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3349's earnings have grown by 2.6% per year over the past 5 years.
Accelerating Growth: 3349's earnings growth over the past year (9.5%) exceeds its 5-year average (2.6% per year).
Earnings vs Industry: 3349 earnings growth over the past year (9.5%) did not outperform the Consumer Retailing industry 10.5%.
Return on Equity
High ROE: 3349's Return on Equity (11%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 04:54 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/08/31 |
Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
COSMOS Pharmaceutical Corporation is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Arashi Nishizawa | BofA Global Research |
Mitsuru Takayanagi | Citigroup Inc |
Jun Kawahara | Daiwa Securities Co. Ltd. |